Stefano De Servi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11084040/publications.pdf

Version: 2024-02-01

84 papers	9,448 citations	218677 26 h-index	58581 82 g-index
85 all docs	85 docs citations	85 times ranked	7886 citing authors

#	Article	IF	Citations
1	Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 20-27.	3.0	14
2	Management of acute coronary syndromes in older adults. European Heart Journal, 2022, 43, 1542-1553.	2.2	24
3	Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. International Journal of Cardiology, 2021, 328, 22-28.	1.7	14
4	Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback. Cardiovascular Drugs and Therapy, 2021, 35, 399-401.	2.6	5
5	Early invasive approach and outcome in elderly patients with NSTEACS: randomised trials, real-world data and guideline recommendations. EuroIntervention, 2021, 17, 20-21.	3.2	1
6	Association of Sex with Outcome in Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Medicine, 2021, 134, 1135-1141.e1.	1.5	6
7	Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Non-Valvular Atrial Fibrillation Patients: Results of A Real-World Study in a Metropolitan Area of Northern Italy. Journal of Clinical Medicine, 2021, 10, 4536.	2.4	5
8	Validation and Additive Predictive Value of the Academic Research Consortiumâ€"High Bleeding Risk Criteria in Older Adults. Thrombosis and Haemostasis, 2021, 121, 1255-1257.	3.4	4
9	Fifteen-Year Trends of Cardiogenic Shock and Mortality in Patients with Diabetes and Acute Coronary Syndromes. American Journal of Medicine, 2020, 133, 331-339.e2.	1.5	9
10	Characteristics and Outcome of Patients â‰¥75 Years of Age With Prior Coronary Artery Bypass Grafting Admitted for an Acute Coronary Syndrome. American Journal of Cardiology, 2020, 125, 1788-1793.	1.6	3
11	A preprocedural risk score predicts acute kidney injury following primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 98, 197-205.	1.7	5
12	Impact of renal dysfunction and acute kidney injury on outcome in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2020, , 2048872620920475.	1.0	5
13	Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome. Circulation, 2020, 142, 150-160.	1.6	93
14	De-escalating dual antiplatelet therapy in patients with acute coronary syndromes: the right strategy to harmonize time-dependent ischemic and bleeding risk in elderly patients?. Journal of Cardiovascular Medicine, 2020, 21, 281-285.	1.5	2
15	Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 730-737.	2.6	4
16	Clinical governance programme in patients with acute coronary syndrome: design and methodology of a quality improvement initiative. Open Heart, 2020, 7, e001415.	2.3	5
17	Trends in management and outcome of patients with non-ST elevation acute coronary syndromes and peripheral arterial disease. European Journal of Internal Medicine, 2019, 59, 70-76.	2.2	9
18	Outcomes of Elderly Patients with ST-Elevation or Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Medicine, 2019, 132, 209-216.	1.5	23

#	Article	IF	Citations
19	Time Course of Ischemic and Bleeding Burden in Elderly PatientsÂWithÂAcute Coronary Syndromes Randomized to Lowâ€Dose Prasugrel or Clopidogrel. Journal of the American Heart Association, 2019, 8, e010956.	3.7	32
20	Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. Journal of Geriatric Cardiology, 2019, 16, 103-113.	0.2	11
21	Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation, 2018, 137, 2435-2445.	1.6	116
22	Is ticagrelor safe in octogenarian patients with non-ST elevation acute coronary syndromes?. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 12-14.	3.0	11
23	The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes. Coronary Artery Disease, 2018, 29, 309-315.	0.7	11
24	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. International Journal of Cardiology, 2018, 259, 20-25.	1.7	18
25	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. Angiology, 2018, 69, 795-802.	1.8	35
26	Comparison of Outcomes of Staged Complete Revascularization Versus Culprit Lesionâ€“Only Revascularization for ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. American Journal of Cardiology, 2017, 119, 508-514.	1.6	8
27	Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation. International Journal of Cardiology, 2017, 248, 369-375.	1.7	22
28	Contemporary Trends and Ageâ€Specific Sex Differences in Management and Outcome for Patients With STâ€Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	67
29	The evolution of post-infarction dissecting hemorrhage into intramural hematoma and sub-epicardial aneurysm. International Journal of Cardiology, 2016, 221, 575-576.	1.7	1
30	Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location. International Journal of Cardiology, 2016, 223, 632-638.	1.7	5
31	A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. American Heart Journal, 2016, 181, 101-106.	2.7	19
32	Invasive Management for Elderly Adults with Acute Coronary Syndrome: Where Are We Now?. Journal of the American Geriatrics Society, 2016, 64, 2396-2397.	2.6	4
33	Which long-term antiplatelet regimen for patients with acute coronary syndromes?. Cardiovascular Drugs and Therapy, 2016, 30, 333-338.	2.6	0
34	Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial. American Heart Journal, 2016, 173, 1-7.	2.7	4
35	Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. European Journal of Heart Failure, 2015, 17, 1124-1132.	7.1	95
36	Effect of an Invasive Strategy on Outcome in Patients â‰¥75 Years of Age With Non-ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2015, 115, 576-580.	1.6	31

#	Article	IF	Citations
37	Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties. International Journal of Cardiology, 2015, 181, 443-445.	1.7	4
38	Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 441-452.	1.0	81
39	Sex-Related Outcomes in Elderly Patients Presenting With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2015, 8, 791-796.	2.9	39
40	A Risk Score for Predicting 1-Year Mortality in Patients â‰¥75 Years of Age Presenting With Non-ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2015, 116, 208-213.	1.6	19
41	Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet, The, 2015, 385, 2371-2382.	13.7	345
42	Renal dysfunction, coronary revascularization and mortality among elderly patients with non ST elevation acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 453-460.	1.0	18
43	Acute Kidney Injury in Elderly Patients With Non-ST Elevation Acute Coronary Syndrome. Angiology, 2015, 66, 826-830.	1.8	8
44	Impact of Gene Polymorphisms, PlateletÂReactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in PatientsÂWithÂNonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 1117-1127.	2.9	38
45	Early invasive versus selectively invasive strategy in patients with nonâ€STâ€segment elevation acute coronary syndrome: Impact of age. Catheterization and Cardiovascular Interventions, 2014, 83, 686-701.	1.7	34
46	Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 363-372.	1.0	38
47	Anemia in octogenarians with non-ST elevation acute coronary syndrome: Aging or disease?. International Journal of Cardiology, 2014, 176, 1147-1149.	1.7	12
48	Oneâ€Year Mortality in Elderly Adults with Nonâ€<scp>ST</scp>â€Elevation Acute Coronary Syndrome: Effect of Diabetic Status and Admission Hyperglycemia. Journal of the American Geriatrics Society, 2014, 62, 1297-1303.	2.6	27
49	Renal function estimation and one-year mortality in elderly patients with non-ST-segment elevation acute coronary syndromes. International Journal of Cardiology, 2014, 174, 127-128.	1.7	15
50	Treatment of Acute Coronary Syndromes in the Elderly and in Patients With Comorbidities. Revista Espanola De Cardiologia (English Ed), 2014, 67, 564-573.	0.6	18
51	Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes â€" results from the BASKET PROVE trial. International Journal of Cardiology, 2013, 168, 3802-3806.	1.7	26
52	Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease. International Journal of Cardiology, 2013, 168, 2381-2388.	1.7	15
53	Trilogy: In search of the lost ring. International Journal of Cardiology, 2013, 167, 1638-1639.	1.7	0
54	Causes of Death in Patients â‰¥75 Years of Age With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2013, 112, 1-7.	1.6	34

#	Article	IF	Citations
55	How to reduce mortality in ST-elevation myocardial infarction patients treated with primary percutaneous coronary interventions: cut the bleeding. Current Medical Research and Opinion, 2013, 29, 189-194.	1.9	7
56	The bivalirudin paradox. Journal of Cardiovascular Medicine, 2013, 14, 334-341.	1.5	9
57	Detection of Tissue Factor Antigen and Coagulation Activity in Coronary Artery Thrombi Isolated from Patients with ST-Segment Elevation Acute Myocardial Infarction. PLoS ONE, 2013, 8, e81501.	2.5	21
58	Defining high-risk patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention: A comparison among different scoring systems and clinical definitions. International Journal of Cardiology, 2012, 157, 207-211.	1.7	4
59	Early Aggressive Versus Initially Conservative Treatment in Elderly Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2012, 5, 906-916.	2.9	215
60	How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial?. International Journal of Cardiology, 2011, 149, 265-267.	1.7	10
61	Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Current Medical Research and Opinion, 2011, 27, 2117-2122.	1.9	4
62	Importance and limits of pre-hospital electrocardiogram in patients with ST elevation myocardial infarction undergoing percutaneous coronary angioplasty. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 526-532.	2.8	26
63	LombardIMA: a regional registry for coronary angioplasty in ST-elevation myocardial infarction. Journal of Cardiovascular Medicine, 2011, 12, 43-50.	1.5	11
64	NT pro-B-type natriuretic peptide levels are related to microvascular reperfusion in patients undergoing direct percutaneous transluminal coronary angioplasty for anterior ST-segment elevation myocardial infarction. Journal of Cardiovascular Medicine, 2010, 11, 359-364.	1.5	2
65	Impact of Acute Coronary Syndromes on Two-Year Clinical Outcomes in Patients With Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents. American Journal of Cardiology, 2010, 105, 174-178.	1.6	11
66	Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries. New England Journal of Medicine, 2010, 363, 2310-2319.	27.0	243
67	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. European Heart Journal, 2010, 31, 943-957.	2.2	548
68	Sex-related differences in patients undergoing percutaneous unprotected left main stenting. EuroIntervention, 2010, 5, 795-800.	3.2	18
69	Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy, 2009, 7, 17-23.	1.5	5
70	Ostial and midshaft lesions vs. bifurcation lesions in 1111 patients with unprotected left main coronary artery stenosis treated with drug-eluting stents: results of the survey from the Italian Society of Invasive Cardiology. European Heart Journal, 2009, 30, 2087-2094.	2.2	112
71	Temporal Pattern of Ischemic Events in Relation to Dual Antiplatelet Therapy in Patients With Unprotected Left Main Coronary Artery Stenosis Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2009, 53, 1176-1181.	2.8	16
72	High-risk non-ST-segment elevation myocardial infarction versus ST-segment elevation myocardial infarction: same behaviour and outcome?. Journal of Cardiovascular Medicine, 2009, 10, S13-S16.	1.5	17

#	Article	IF	Citations
73	Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 51, 2212-2219.	2.8	160
74	Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.7	26
75	Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction: data from the BLITZ study. Journal of Cardiovascular Medicine, 2008, 9, 1045-1051.	1.5	5
76	Circulating CD34-positive cell number is related to effective myocardial reperfusion in acute myocardial infarction treated with primary coronary angioplasty. Journal of Cardiovascular Medicine, 2008, 9, 677-682.	1.5	3
77	Early aggressive vs. initially conservative treatment in elderly patients with non-ST-elevation acute coronary syndrome: The Italian Elderly ACS study. Journal of Cardiovascular Medicine, 2008, 9, 217-226.	1.5	12
78	Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2007, 357, 2001-2015.	27.0	5,933
79	Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. European Heart Journal, 2006, 27, 393-405.	2.2	54
80	Significance of total and differential leucocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty. European Heart Journal, 2006, 27, 2511-2515.	2.2	67
81	Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with nonâ€“ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. American Heart Journal, 2005, 150, 401.e9-401.e14.	2.7	21
82	Non-stâ€“elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome. American Heart Journal, 2004, 147, 830-836.	2.7	66
83	Epidemiology of acute myocardial infarction in the Italian CCU network The BLITZ Study. European Heart Journal, 2003, 24, 1616-1629.	2.2	111
84	Integrated Analysis of Myocardial Blush and ST-Segment Elevation Recovery After Successful Primary Angioplasty. Circulation, 2002, 106, 313-318.	1.6	189